Osmotica Pharmaceuticals is a pharmaceuticals business based in the US. Osmotica Pharmaceuticals shares (OSMT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.87 – the same closing value as a week prior. Osmotica Pharmaceuticals employs 302 staff and has a trailing 12-month revenue of around $165.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.87 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $1.15 |
| 200-day moving average | $2.48 |
| Wall St. target price | $5.75 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.60 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.87 from 2022-03-22
| 1 week (2024-10-05) | N/A |
|---|---|
| 1 month (2024-09-12) | N/A |
| 3 months (2024-07-12) | N/A |
| 6 months (2024-04-12) | N/A |
| 1 year (2023-10-12) | N/A |
|---|---|
| 2 years (2022-10-12) | N/A |
| 3 years (2021-10-15) | 1.94 |
| 5 years (2019-10-16) | 4.41 |
Valuing Osmotica Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Osmotica Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Osmotica Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $33 million.
The EBITDA is a measure of a Osmotica Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $165.9 million |
|---|---|
| Gross profit TTM | $103.4 million |
| Return on assets TTM | -3.27% |
| Return on equity TTM | -102.75% |
| Profit margin | -60.32% |
| Book value | $0.87 |
| Market Capitalization | $92.5 million |
TTM: trailing 12 months
We're not expecting Osmotica Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Osmotica Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Osmotica Pharmaceuticals's is 1.9599. This would suggest that Osmotica Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. .
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.